MTOR and Immunodeficiency: The adjuvant use of PI3K and mTOR inhibitors in these cases has been hypothesized for a long time and underpinned by mouse studies 12, 33 and the aforementioned p110δ loss‐of‐function immunodeficiencies 28, 29.